All posts by imreal

Founders of Dognomics Partner with the Creative Digital Agency Digital Silk to Launch Their Dog DNA Test Kits in the U.S.


Dognomics homepage designed by Digital Silk

Founders of Dognomics partnered with Digital Silk to launch and grow their brand online

“Your website is a market tool – THE marketing tool, in fact. This is where you educate your prospects on your offering and move them through the conversion funnel until they are ready to buy.” – Stephanie Sharlow, VP at Digital Silk

Clinomics, founders of dog DNA test brand Dognomics, partnered with creative digital agency Digital Silk to introduce their at-home kits to U.S.-based dog parents and grow their brand online.

Working closely with the team behind Dognomics, Digital Silk’s specialists established the foundation of brand’s digital presence, including brand strategy and visual identity, eCommerce website and online marketing channels.

Leveraging the brand’s unique value proposition coupled with market research, competitor and audience analysis, the agency formulated Dognomic’s authentic brand and identified their optimal market positioning. From visual identity to messaging, the brand balances its complex, scientific roots with their team’s simple and enthusiastic “love for dogs.”

Digital Silk’s Director of Brand Strategy Courtney Bozigian said, “To resonate with consumers, the brand needs to tell the story and use the language that speaks to their needs,” said Bozigian. “Combining “a passion for science with a love for dogs,” Dognomics’ messaging needed to communicate the highly scientific and precise process of ”unlocking a dog’s DNA,” as well as the joy and the love we put into caring for our pets.”

Digital Silk’s award-winning brand designers completed Dognomics’ visual identity with a signature purple and blue packaging design, starring a mystery dog, ready to learn its heritage.

Digital Silk’s team of digital strategists and UX/UI designers translated the brand’s visual identity into a strategically designed eCommerce website. From conversion funnel planning to web design and development, the agency created a custom e-store optimized for search engines and conversions.

According to Digital Silk’s Vice President Stephanie Sharlow, strategic website planning is key to building a high-performance website, particularly one that introduces a new product or brand to the market.

“Your website is a market tool – THE marketing tool, in fact,” said Sharlow. “This is where you educate your prospects on your offering and move them through the conversion funnel until they are ready to buy. With Dognomics, we focused on communicating the value of dog DNA testing, the credibility and precision of Dognomics’ “DNA unlocking” process, and the simplicity of using their product.”

The team behind Dognomics and Digital Silk continue to work closely together to grow the brand’s presence in the U.S. by strengthening the brand’s following and engagement on key digital marketing channels.

About Digital Silk:

Digital Silk is a creative digital agency focused on growing brands online. From custom websites to digital marketing, Digital Silk creates SUPERIOR digital experiences to drive higher conversions, greater brand engagement and measurable results.

Share article on social media or email:

The PAINWeek 2022 National Conference Presents the Advanced Practice Providers Track on Wednesday, September 7


News Image

“PAINWeek is committed to providing advanced pain education to APPs at all stages of their careers, and 2022 promises to be the best conference yet..”

Advanced Practice Providers are making a difference in pain management. Recent articles have asked, “can advanced practice providers be the answer to the nursing crisis?” [1] and noted that NPs and PAs are/will be 67.3% of the practitioners added to the workforce between 2016 and 2030, outpacing physicians. [2]

Presenter Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC, of the Stanford Outpatient Medical Center, Division Pain Medicine, in Redwood City, California, commented, “as APP attendance at PAINWeek continues to grow, so does the quality of its APP track offerings. PAINWeek is committed to providing advanced pain education to APPs at all stages of their careers, and 2022 promises to be the best conference yet. My session, Green Acres: Pregnancy & Pain in Rural Communities, will highlight the importance of adequate pain management during pregnancy.”

Jeremy Adler, DMSc, PA-C, will discuss his trials, tribulations, and successes in the PA Perspective on Owning Your Own Practice. He commented, “managing the complexity of patients with chronic pain generally requires a skilled and dedicated team. We have found that our team has thrived through joint ownership of the practice between PAs and physicians. This session will introduce some of the ways PAs can be either as owners, shareholders, or entrepreneurial in meeting the needs of patients.” Dr. Adler is Senior Pain Management PA and Chief Operating Officer at Pacific Pain Medicine Consultants in California.

Lo and Behold: The Clinical Nurse Anesthetist Experience in Pain Management will be presented by Jackie Rowles, DNP, CRNA, ANP-BC, NSPM-C. Ms. Rowles stated, “PAINWeek is the largest gathering of pain clinicians from across the nation and provides an avenue for all disciplines to come together to network and learn from one another. My lecture details the pathway, subspecialty education, and typical clinical practice day of a Certified Registered Nurse Anesthetist Pain Practitioner.” Ms. Rowles is an associate professor of professional practice and director of the advanced pain management fellowship at Texas Christian University.

Other courses in the APP Track include:

  • Neuromodulation for Advanced Practice Providers
  • Bridging the Gap: The Transitional Pain Service and Role of the NP

PAINWeek will present over 75 CME/CE credit hours in tracks such as Behavioral Pain Management, Chronic Pain Syndromes, Health Coaching, Interventional and Integrative Pain Management, Medical/Legal, Neurology, Physical Therapy, Pharmacotherapy, and Psychedelics. Master Classes, Special Interest Sessions, and sponsored courses complement the agenda, along with tracks presented by the American Society of Interventional Pain Physicians and the International Pelvic Pain Society.

For more information, click here, or visit painweek.org.

PAINWeek accreditation provided by Global Education Group:

Global Education Group focuses on producing partnership-based CME for healthcare practitioners. The Global team works with a select group of medical education companies, associations, academic institutions, and healthcare facilities to develop and accredit live healthcare conferences and workshops as well as online activities. With each partnership or joint providership, Global brings accreditation expertise, project management excellence and grant funding intelligence. Based in Littleton, Colo., Global has accreditation with commendation from the ACCME and accredited with distinction from the ANCC. Global also holds accreditations to offer continuing education for nurse practitioners, pharmacists, dietitians, dentists, and psychologists. Global is a division of Ultimate Medical Academy.

1. https://www.mgma.com/resources/human-resources/can-advanced-practice-providers-be-the-answer-to-t

2. https://www.fiercehealthcare.com/practices/growth-advanced-practice-clinicians-will-outpace-physicians-projections-predict

Share article on social media or email:

The Healthcare Technology Report’s Top 100 Healthcare Technology Companies of 2022


The Healthcare Technology Report is pleased to announce The Top 100 Healthcare Technology Companies of 2022. The awardees on this year’s list represent the absolute best in the healthcare technology space. From companies like Novartis with more than 100,000 team members around the globe, to numerous smaller startups with just a few dozen employees in a single office, these companies are changing the face of the industry. They are leveraging their considerable talent to find innovative solutions to the most pressing issues in healthcare, and they are saving countless lives and extending healthspans in the process.

A few of this year’s awardees include Hologic, whose growth across breast and skeletal health, diagnostic solutions, and GYN surgical solutions is driven by the clinically proven ability of its products to detect, diagnose, and treat illnesses and other health conditions earlier and better; Integra LifeSciences, which offers a broad portfolio of products and solutions for dural access and repair, cerebral spinal fluid management, and neuro-critical care; and Axtria, whose best-in-class cloud-based analytics platforms have leveraged AI and machine learning to help life sciences operators make the most of their data for the benefit of their clients.

The top 100 companies this year represent a range of specialties, from genomics to pharmaceuticals, lab testing, therapeutics, data analysis, and much more. What they have in common is the impact they are having on patients’ lives, whether through direct treatment or by providing advanced, game-changing products and services to treatment providers. They are driving the industry forward and creating an environment in which better care for all is possible. Please join us in celebrating The Top 100 Healthcare Technology Companies of 2022.

Novartis, Stryker, Edwards Lifesciences, Centura Health, Hologic, Access Healthcare, CitiusTech, Integra LifeSciences, JAZZ Pharmaceuticals, Axtria, Horizon Therapeutics, Leica Biosystems, Modere, Penumbra, Practo, Tempus, Verily, Carbon Health, GHX, TELUS Health, Tandem Diabetes Care, Cue Health, Certara, Thrive, Organogenesis, Alto Pharmacy, Ascom, DispatchHealth, Weave, Ro, Merative, Komodo Health, Zynex, Tebra, Telstar, MedGenome, Wellspect Healthcare, Somatus, Sophia Genetics, Flo Health, H1, Intra-Cellular Therapies, Augmedix, DentalMonitoring, Meditab Software, Immunocore, Roivant Sciences, 98point6, Seven Bridges, ExactCare Pharmacy, Helix, LeanTaaS, Clinical ink, InterVenn Biosciences, Omada Health, Quanticate, BillionToOne, Kaia Health, Biodesix, Exagen, Big Health, Accelerate Diagnostics, Avalon Healthcare Solutions, Enable Injections, Pluri Inc., Krystal Biotech, Precision Medical Products, Hallmark Health Care Solutions, ImagineSoftware, BioIQ, Qventus, Sino Biological, Sedera, Sony Biotechnology, Sotera Health, Precision Value & Health, Intarcia Therapeutics, Caption Health, Transcenta, Tosoh Bioscience, Xoran Technologies, Ocimum Biosolutions, RXNT, Providence Medical Technology, Canary Medical, Cynerio, Bright.md, Exponent Health, HitGen, OriGen Biomedical, Force Therapeutics, Relias, D2 Solutions, renegade.bio, Patagonia Health, Lazurite, Vizzia Technologies, Commonwealth Diagnostics International, Fisher Wallace Laboratories, XIL Health.

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Gastroenterologist, Dr. Natan N. Krohn Named 2022 NJ Top Doc


Dr. Natan N. Krohn

Dr. Natan N. Krohn

Natan N. Krohn, MD of Gastroenterology Associates Of New Jersey in Clifton, New Jersey is a double board certified gastroenterologist and has been approved by NJ Top Docs for 2022.

Prior to his position at the Gastroenterology Associates Of New Jersey, Dr. Krohn conducted research for Marion Bessin Liver Research Center and the Albert Einstein College of Medicine in Bronx, NY on various topics relevant to the medical community.

He completed a fellowship in gastroenterology and hepatology at the Montefiore Medical Center in Bronx, NY and a residency in internal medicine at Mount Sinai Hospital in New York, NY. Dr. Krohn also received his medical degree with special distinction for research in hepatology from the Albert Einstein College of Medicine and a Bachelor of Arts in history with summa cum laude honors from Yeshiva University in New York, NY.

In addition to his extensive research during his medical training, Dr. Krohn has multiple publications and has received academic awards including the Samuel Belkin Scholarship and the Ira Marienhoff Scholarship.

To learn more about NJ Top Doc, Dr. Natan Krohn, please visit: https://njtopdocs.com/nj-doctors/drnatankrohn/

—

About Us

NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Asymmetrex® Interviewed by Tech Company News About Plans to Introduce Online Rapid-Counting Calculators for Quantifying Therapeutic Tissue Stem Cells


Preview of an online rapid stem cell-counting calculator portal page

Counting tissue stem cells accurately and fast is something stem cell science and stem cell medicine have needed for a very long time. It’s here now,…

Tech Company News and its affiliated online new outlet, Superb Crew, have been following the stem cell biotechnology business progress of Massachusetts stem cell biotechnology company Asymmetrex® for several years. In TCN’s most recent feature article interviewing Asymmetrex® President and CEO James L. Sherley, M.D., Ph.D., TCN learned more about the company’s new plans to introduce, some time in 2022, the first-ever rapid-counting calculators for determining the specific fraction and dosage of therapeutic tissue stem cells.

The first indication of Asymmetrex®’s plans appeared in a lead article in the recent June issue of the online newsletter of the Parent’s Guide to Cord Blood Foundation. The Parent’s Guide article described Asymmetrex®’s first-in-kind tissue stem cell counting technology and its applications, highlighting use for determining the dosage of cord blood stem cell treatments. Though the Parent’s Guide article anticipated Asymmetrex®’s new online rapid-counting calculators, it had few specifics on how they worked and when they would be available.

TCN learned that online portals for the new rapid-counting calculators are already being evaluated by several academic groups and research agencies in the stem cell and regenerative medicine space. The company plans to have its first official launch of online rapid-counting calculator portals for free previewing by cell culture core facilities nationwide by mid-September of this year.

The first online portal for preview will debut calculators for CD34+ umbilical cord blood stem cells and fat-tissue derived mesenchymal stem cells. Both stem cell types are presently actively utilized in stem cell research and stem cell medicine. With the new online calculators, for the first time, investigators using preparations containing these cells will be able to quantify their specific fraction or dosage routinely.

“By making them available to the directors of cell culture core facilities first, more stem cell investigators can get access to them sooner,” says CEO Sherley. “Every 3 to 4 months, Asymmetrex® will roll out new calculators into these portals for preview. And we can also provide custom rapid-counting calculators for user-specific stem cell sources and production conditions. Counting tissue stem cells accurately and fast is something stem cell science and stem cell medicine have needed for a very long time. It’s here now, and will appear in greater volume in September.”

About Asymmetrex®

Asymmetrex®, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – stem cell-specific quantification and stem cell expansion – that have stood in the way of more-effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex® markets kinetic stem cell (KSC) counting, the first technology for determination of the dose and quality of tissue stem cell preparations for use in stem cell transplantation medicine and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute | BioFabUSA (ARMI) and the Massachusetts Biotechnology Council (MassBio).

Share article on social media or email:

Unitek College to Receive School of Distinction Award in Nevada


Unitek College is one of California and Nevada’s reputable healthcare colleges.

As a School of Distinction, Unitek College will be formally recognized throughout the 2022 ACCSC Professional Development Conference.

Unitek College is thrilled to announce that on September 21, 2022, they will be presented with a 2021 – 2022 ACCSC School of Distinction Award for their Reno campus. Marilyn Lim-Carreon, the Campus Director, will accept the award on behalf of the entire Reno campus. This prestigious ceremony will be held at the ACCSC’s Professional Development Conference in Reston, Virginia.

The ACCSC School of Distinction Award commends institutions that have overcome the rigors of accreditation and produced educational programs of the highest quality. As a School of Distinction, Unitek College will be formally recognized throughout the 2022 ACCSC Professional Development Conference. The theme of the conference, “A Community of Partners in Education,” highlights a shared goal between ACCSC and Unitek: building partnerships within higher education to promote student excellence.

“We are thrilled to celebrate our accomplishments at the Reno Campus,” said Dr. Navneet Bhasin, Chief Operations Officer at Unitek College. “It has been a year of growth and opportunity at Unitek, and we look forward to celebrating our success throughout the 2022 ACCSC Professional Development Conference.”

The Accrediting Commission of Career Schools and Colleges (ACCSC) designed this conference to provide various opportunities for accredited institutions. At the event, participants will have the chance to promote student excellence, strengthen support for workforce development, and help fill the skills gap in the United States. Join Unitek College and other school representatives for a celebration of educational achievements at the Professional Development Conference.

“We have created a welcoming culture of inclusiveness where everything we do in Reno is centered around our students,” said Marilyn Lim-Carreon, Campus Director of Unitek College Reno. “We are committed to excellence because it is what our students, our staff, and our community deserve!”

Unitek College is one of California and Nevada’s reputable healthcare colleges. Every Unitek program teaches the clinical technique and theory used in the field today. Equipped with a multitude of sought-after skills, Unitek graduates are prepared to excel in many of the fastest-growing careers in healthcare and nursing.

Share article on social media or email:

Pharmaceutical Advertising and Promotion Review Program Workshop on Sept. 20-21, 2022 in Philadelphia, PA


Building a World-Class Pharmaceutical Advertising and Promotion Review Program

A Two-Day Interactive Workshop Presented by PhillyCooke Consulting and FDAnews

Sept. 20-21, 2022 • Philadelphia, PA

https://wcg.swoogo.com/advertising-and-promotion

The world of pharmaceutical advertising and promotion is filled with talented people, but they still need help. Not with creating better ads and promotions, they already know how to do that, but for making sure their promotional activities aren’t magnets for FDA untitled letters.

Come to Philadelphia in September for two days of full learning. Attendees will arrive back home with a bag of tricks and tips to ensure their marketing efforts stand up to FDA scrutiny.

Attendees will be up-to-date with the latest regulatory and enforcement trends. The agenda includes:

  • Understanding Preapproval Communications: Don’t get on the FDA’s or SEC’s radar screens before a product is even approved. Learn how to properly disclose information and remain in compliance.
  • How to Maximize Disease Awareness Communications: Take away valuable tips and tricks for using disease awareness communications before and after approval.
  • Hurray! You’re Approved: Build the most aggressive but compliant campaign from first day of approval to commercial launch.
  • Assuring Promotions Meet FDA Off-Label Standards: Successfully navigate traps that can earn drugmakers a warning letter.
  • Itching to do More with Social Media? Discover how to get the message out there, without crossing the line.


The workshop binder includes checklists for promotion approvals/effective review, relevant sections of Form 2253 [CFR], PhRMA’s Principles on DTC Advertising and Principles on Interactions with Healthcare Professionals and more.

Workshop Details

Building a World-Class Pharmaceutical Advertising and Promotion Review Program

A Two-Day Interactive Workshop Presented by PhillyCooke Consulting and FDAnews

Sept. 20-21, 2022 • Philadelphia, PA

https://wcg.swoogo.com/advertising-and-promotion

Price:

Early Bird Price: Register by Aug. 26, 2022 — $1,597

After Aug. 26, 2022 — $1,797

Easy Ways to Register:

Online: https://wcg.swoogo.com/advertising-and-promotion

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ newsletters, books, databases, webinars and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.

Share article on social media or email:

New Fenway Health Study Examines The “Social Contagion” Hypothesis of Transgender and Gender Diverse Identities


Blue rectangular Fenway Health logo with white text

The hypothesis that transgender and gender diverse youth assigned female at birth identify as transgender due to social contagion does not hold up to scrutiny and should not be used to argue against the provision of gender-affirming medical care for adolescents.

A study published today in Pediatrics, using a large national dataset of adolescents in the U.S., provided evidence against the notion that adolescents in the U.S. come to identify as transgender due to “social contagion.”

The study also found that the percentage of teens openly identifying as transgender or gender diverse (TGD) did not increase between 2017 and 2019. Additionally, contrary to past research with smaller samples, teens assigned female at birth were not overrepresented among TGD adolescents in the U.S. It is the largest study to date to examine the controversial hypothesis that more adolescents who were assigned female at birth have identified as TGD because of “social contagion.” The study adds important new knowledge to the evolving field of transgender health care and ongoing public debate of legislative measures regulating access to gender-affirming health care.

“The hypothesis that transgender and gender diverse youth assigned female at birth identify as transgender due to social contagion does not hold up to scrutiny and should not be used to argue against the provision of gender-affirming medical care for adolescents,” said study senior author Dr. Alex S. Keuroghlian, who directs the National LGBTQIA+ Health Education Center at The Fenway Institute and the Massachusetts General Hospital Psychiatry Gender Identity Program.

Researchers used data from the 2017 and 2019 Youth Risk Behavior Survey to explore the hypothesis known as “rapid-onset gender dysphoria” (ROGD), which posits that young people begin to identify as TGD for the first time as adolescents rather than as prepubertal children and that this identification and subsequent gender dysphoria are the result of social contagion. The ROGD hypothesis further asserts that youth assigned female sex at birth are more susceptible to social contagion than those assigned male sex at birth.

In “Sex Assigned At Birth Ratio Among Transgender and Gender Diverse Adolescents in the United States,” researchers examined data reported by 91,937 adolescents in 2017 and 105,437 adolescents in 2019 from 16 states that participated in the national Youth Risk Behavior Survey. The data refute the ROGD hypothesis in the following ways:


  • The total percentage of TDG adolescents decreased from 2.4% (2,161 TGD adolescents out of 91,937 overall) in 2017 to 1.6% (1,640 TDG adolescents out of 105,437 overall) in 2019. This decrease in the overall percentage of adolescents identifying as TGD is incongruent with the ROGD hypothesis.
  • Between 2017 and 2019, the sex assigned at birth ratio of TGD adolescents shifted toward more adolescents assigned female at birth, which would initially appear to support the ROGD hypothesis. (In 2017, the ratio of those assigned male at birth compared with those assigned female at birth was 1.47 to 1; in 2019, the ratio of those assigned male at birth compared with those assigned female at birth was 1.16 to 1.) However, the shift in sex ratio was driven by a decrease in the proportion of those assigned male at birth openly identifying as TGD, which further undermines the ROGD hypothesis. The percentage of adolescents assigned female at birth decreased from 2017 to 2019.
  • The ROGD hypothesis asserts that youth are drawn to come out as TGD to avoid the stigma associated with being a sexual minority or because being TGD will make them more popular among their peers. Yet rates of bullying victimization and suicidality were higher among TGD youth as compared with their cisgender peers, including their cisgender sexual minority peers. Both findings are incongruent with the notion that some youth openly identify as TGD in an attempt to flee the stigma of being a sexual minority or because being TGD will make them more popular among their peers.

The ROGD hypothesis, first published in 2018, immediately gained influence in public policy debates with coverage by publications ranging from The Economist to Science. This past June, Florida’s Agency for Health Care Administration referred to reports citing the ROGD hypothesis as justification for a new policy implemented this past June prohibiting the use of Medicaid funds for gender-affirming health care. In July, the popular children’s book author J.K. Rowling tweeted to her over 13 million followers that gender-affirming health care harms adolescents.

Yet the 2018 study popularizing the ROGD hypothesis was based on surveys completed by 256 parents with no input from TGD youth. Parents were recruited from three websites, two of which are anti-transgender. One, 4thWaveNOW, describes itself as a “community of people who question the medicalization of gender-atypical youth.” The tagline for the second site, Transgender Trend, is “No child is born in the wrong body.”

“The idea that attempts to flee sexual minority stigma drive teenagers to come out as transgender is absurd, especially to those of us who provide treatment to TGD youth” said study lead author Dr. Jack Turban, incoming Assistant Professor of Child & Adolescent Psychiatry at The University of California, San Francisco. “The damaging effects of these unfounded hypotheses in further stigmatizing transgender and gender diverse youth cannot be understated. We hope that clinicians, policymakers, journalists, and anyone else who contributes to health policy will review these findings.”

“Sex Assigned At Birth Ratio Among Transgender and Gender Diverse Adolescents in the United States,”is available online here.

Share article on social media or email:



Direct Care Innovations Has Completed EVV Aggregation in California & Now Offers All-In-One Direct Care Software Solutions for the Caregiving Industry


With EVV solutions available as part of their full-service direct care business management software, Direct Care Innovations is meeting the needs of everyday challenges for those who work in the caregiving industry in California.

Direct Care Innovations announced today that they have completed aggregation activities with SanData, a health care management company, in order to become an alternate vendor for Electronic Visit Verification (EVV) in the state of California. EVV is a mobile technology solution that offers an efficient way for the direct care industry to electronically verify that in-person services were delivered to clients. Direct Care Innovations has already completed aggregation in 30 states and is currently working on 18 more.

EVV Services for All Direct Care Agencies

The aggregation process required Direct Care Innovations to pass testing that would allow the company to become an alternate vendor for EVV. Now that aggregation is complete, they are able to offer EVV to current and new clients such as respite care providers, managed care organizations, personal attendant care, consumer direction agencies, supported living services, Medicaid and Medicare agencies, and government agencies.

One Platform, Multiple Software Solutions

Along with EVV services, Direct Care Innovations also provides an integrated business management platform for caregiving agencies, making Direct Care Innovations a one-stop service for all of their direct care software solutions.


  • Real-time authorization management
  • Training and compliance
  • Employee time and attendance software
  • Billing
  • Scheduling and shift trading
  • Real-time reporting
  • Custom automated workflows

Compassionate & Effective Business Management for the Caregiving Industry Direct Care Innovations already serves some of the largest agencies in California with their industry-specific direct care software and top-notch customer service. Their all-in-one software system empowers clients to seamlessly run every aspect of their business, serving their customers with effective and compassionate care.

Features and benefits of Direct Care Innovations’ EVV digital solution include:

  • Facial recognition technology
  • GPS-enabled location tracking
  • Tracking of travel time and employee hourly shifts
  • Real-time balance and budget management
  • Configurable notification settings

EVV is currently available for all caregiving industries in the state of California. For more information on EVV, visit Direct Care Innovations or call for a demo.

About Direct Care Innovations: Direct Care Innovations partners with providers and government agencies in the Medicaid, Medicare, and Managed Care Markets by providing them with an integrated, all-inclusive business management platform. As a leader in direct care software solutions, Direct Care Innovations‘ goal is to assist these agencies by streamlining their administrative responsibilities so they can devote more of their resources to providing high-quality care for their patients. Direct Care Innovations’ core values include exceeding compliance standards, promoting quality of care, and advocating for higher direct care wages.

Share article on social media or email:

Rendr Receives Top Performance Scores in CMS’ Value-Based Care Programs


Rendr, a primary care physician group serving approximately 100,000 Asian Americans in New York City, released its 2021 Star Quality Ratings from the Centers for Medicare & Medicaid Services (CMS). Rendr earned the following overall Star Quality Ratings for the following New York City insurers:

· 4.8 stars from UnitedHealthcare Medicare

· 4.7 stars from Healthfirst Medicaid

· 4.3 stars from Healthfirst Medicare

· 4 stars from Emblem

· 4 stars from WellCare

CMS created the star rating system to help people see the differences of Medicare Advantage plans and Part D prescription drug plans. CMS rates these plans each year, on a scale from one to five stars, illustrating the differences of performance and quality.

Rendr’s performance scores resulted from a series of initiatives to improve health outcomes, access to care and the overall patient experience. Specialized clinical, analytic and operational teams are integrated to target gaps in various types of patient care, including breast cancer screenings and diabetes-related eye exams.

Rendr’s results in patient quality improvements have been recognized by major insurance payors. “We are committed to providing the diverse communities we serve throughout New York with greater access to quality, cost-effective care,” says Chris Law, National Vice President of UnitedHealthcare’s Asian Initiatives.“ We are grateful for the collaborative relationships we share with care providers like Rendr, who are committed to improving care quality and providing culturally relevant services to their community.”

According to the American Cancer Society, early detection is key to give patients the best chance for a positive health outcome. As the healthcare industry transitions to more risk-based care models, Rendr proactively screens chronic diseases, identify health risks and treat patients in an integrated approach. Rendr launched a key clinical initiative to improve early cancer detection screening rate by coordinating with third-party diagnostic imaging centers to make scheduling mammograms easy for patients. “We’re proud to make our communities healthier and build the best practices for early cancer detection and chronic disease prevention,” says Dr. David Shih, Rendr’s Chief Medical Officer. “Rendr was able to improve the breast cancer screening metric from what is historically a 1-star rating to the maximum 5-star. We identify opportunities for improvement like this to further make our processes better.”

Rendr also developed new clinical protocols, allowing patients with diabetes to have eye exams as part of their primary care visits. Early detection of retinopathy, a complication of diabetes that affects the eyes, may help save patients’ vision if detected early, says the American Diabetes Association. As a result, Rendr received a maximum score of 5-stars for this CMS measure.

About Rendr:

Rendr is the largest primary care focused, multi-specialty physician group dedicated to serving medically underserved Asian populations in New York City. The physician group was founded in 2019 with a mission to provide world-class health care services and serve kindness to immigrant communities. Currently, Rendr has more than 100 medical providers serving a patient population of approximately 100,000 at its 39 locations across Brooklyn, Manhattan, and Queens. Rendr is a member of managed services organization CareAbout’s network and is financially backed by Ascend Capital Partners, a healthcare focused private equity firm. For more information, please visit rendrcare.com.

Press Contact

Ruby.li@rendrcare.com

Share article on social media or email: